Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 7/20 | 0.62 |
| ▸ | ITGAV | P06756 | 1/20 | 0.62 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 2/20 | 0.38 |
| ▸ | CCKBR | P32239 | 2/20 | 0.38 |
| ▸ | PYGL | P06737 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028110 | 0.94 | ITGB1 (0.55) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4624866 | 0.91 | ITGB1 (0.52) | ITGB1ITGAVITGA4ITGB7CCKAR | |
| SCHEMBL3313211 | 0.90 | ITGB1 (0.51) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4625488 | 0.87 | ITGB1 (0.59) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL3314603 | 0.84 | ITGB1 (0.45) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4625161 | 0.84 | ITGB1 (0.45) | ITGB1ITGAVABL1CCKARCCKBR | |
| SCHEMBL1030227 | 0.84 | ITGB1 (0.46) | ITGB1ITGAVABL1CCKARCCKBR | |
| SCHEMBL6142438 | 0.82 | ITGB1 (0.42) | ITGB1ITGAVITGA4ITGB7CCKAR | |
| SCHEMBL6151284 | 0.82 | ITGB1 (0.47) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4750012 | 0.81 | ITGB1 (0.49) | ITGB1ITGAVABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | ITGB1 274/4885ITGAV 65/4885ITGA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.